MYB as a Subtype Specific Therapeutic Vulnerability in POU2F3+ Small Cell Lung CancerPublished byctscweb.weill.cornell.eduon •1 min readVidushi Durani Cell and Developmental Biology Chairperson: Dr. Jason Lewis Major Sponsor: Dr.cancersmall cell lung cancertherapyvulnerabilityLearn moreShareLegalReport
